Fluctuation dynamo and turbulent induction at low magnetic Prandtl numbers

This paper is a detailed report on a programme of simulations used to settle a long-standing issue in the dynamo theory and demonstrate that the fluctuation dynamo exists in the limit of large magnetic Reynolds number Rm>>1 and small magnetic Prandtl number Pm<<1. The dependence of the critical Rm_c vs. the hydrodynamic Reynolds number Re is obtained for 1<Re<6700. In the limit Pm<<1, Rm_c is ~3 times larger than for Pm>1. The stability curve Rm_c(Re) (and, it is argued, the nature of the dynamo) is substantially different from the case of the simulations and liquid-metal experiments with a mean flow. It is not as yet possible to determine numerically whether the growth rate is ~Rm^{1/2} in the limit Re>>Rm>>1, as should be the case if the dynamo is driven by the inertial-range motions. The magnetic-energy spectrum in the low-Pm regime is qualitatively different from the Pm>1 case and appears to develop a negative spectral slope, although current resolutions are insufficient to determine its asymptotic form. At 1<Rm<Rm_c, the magnetic fluctuations induced via the tangling by turbulence of a weak mean field are investigated and the possibility of a k^{-1} spectrum above the resistive scale is examined. At low Rm<1, the induced fluctuations are well described by the quasistatic approximation; the k^{-11/3} spectrum is confirmed for the first time in direct numerical simulations.Comment: IoP latex, 27 pages, 25 figures, 3 tables. Accepted by New J. Physic

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3&nbsp;years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0&nbsp;years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores &gt;2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores &gt;2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score &gt;2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores &gt;2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores &gt;2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Робастна система керування БПЛА з надмірним вимірювачем

The paper deals with synthesis of robust system assigned for operation on unmanned aerial vehicles. A feature of the system lies in using nonorthoginal measuring instrument. Synthesis of the controller was carried out by means of the robust structural synthesis. Such an approach requires  development of the mathematical model of a plant. Therefore models of longitudinal and lateral motion of an unmanned aerial vehicle` were obtained. These models take into consideration nonorthogonal redundant measuring system, which includes rate gyroscopes based on microelectromechanical systems technology. Matrices of state, control, observation in the state space were obtained using AeroSim Technology. Results of synthesied system simulation are represented. The obtained results can be useful for moving vehicles of the wide class.В статье рассмотрен синтез робастнойї системы, предназначенной для эксплуатации на БПЛА. Особенностью системы является использование неортогонального измерителя. Синтез регулятора был выполнен на основе робастного структурного синтеза. Такой подход основан на создании математической модели объекта управления. Поэтому были получены модели продольного и бокового движения летательного аппарата. В этих моделях учтена неортогональная измерительная система, которая включает скоростные гироскопы, основанные на технологиях микроэлектромеханических систем. Матрицы состояния, управления и наблюдения были получены при помощи технологии Aerosim. Представлены результаты моделирования синтезированной системы. Полученные результаты могут быть полезными для подвижных объектов широкого класса.У статті розглянуто синтез робастної системи, призначеної для експлуатації на БПЛА. Особливістю системи є використання неортогонального вимірювача. Синтез регулятора було виконано на основі робастного структурного синтезу. Такий підхід засновано на створенні математичної моделі об’єкта управління. Тому було отримано моделі поздовжнього та бічного руху літального апарата. В цих моделях враховано неортогональну вимірювальну систему, що включає швидкісні гіроскопи, засновані на технологіях мікроелектромеханічних систем. Матриці стану, управління та спостереження було отримано за допомогою технології Aerosim. Представлено результати моделювання синтезованої системи. Отримані результати можуть бути корисними для рухомих об’єктів широкого класу